The effect of vitamin D supplementation in treatment of patients with epilepsy

The effect of vitamin D supplementation on seizure frequency, mental health parameters, metabolic and genetic profiles in patients with epilepsy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170420033551N5

Enrollment

Registered

2019-07-02

Start date

2019-02-03

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy and recurrent seizures. Epilepsy and recurrent seizures

Interventions

Intervention 1: Intervention group: 50000 IU vitamin D (Zahravi, Tabriz, Iran), every 2 weeks, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), every 2 weeks,

Eligibility

Sex/Gender

All

Age

9 Years to 18 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with epilepsy Individuals aged 9 to 18 years vitamin D insufficiency or deficiency (serum 25- hydroxyvitamin D <30 ng/mL)

Exclusion criteria

Exclusion criteria: History of acute or chronic liver diseases History of renal insufficiency metabolic disorders infectious diseases autoimmune diseases hematologic disorders Taking vitamin D, calcium, and other antioxidant supplements in the last 3 months and during the study

Design outcomes

Primary

Measure	Time frame
Beck depression inventory. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;The frequency of seizures. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: checklist.	—

Secondary

Measure	Time frame
Beck anxiety inventory. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.;Expressed levels of IL-6 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.;Expressed levels of PPAR-?. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.	—

Measure

Time frame

Beck anxiety inventory. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.;Expressed levels of IL-6 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.;Expressed levels of PPAR-?. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: RT-PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Ghaderi

Kashan University of Medical Sciences

ghaderi-am@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026